Novavax (NASDAQ: NVAX) reported Q4 EPS of $0.11, $0.60 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $147 million versus the consensus estimate of $90.25 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.